Evidence map›Paper›PMID 35201850›Full record

ArticleJCO precision oncology2022

Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer.

Gabriella Cirmena, Lorenzo Ferrando, Francesco Ravera, Anna Garuti, Martina Dameri, Maurizio Gallo, Valentina Barbero, Fabio Ferrando, Lucia Del Mastro, Alessandro Garlaschi and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Gabriella CirmenaDepartment of Internal Medicine, University of Genoa, Genoa, Italy.
Lorenzo FerrandoDepartment of Internal Medicine, University of Genoa, Genoa, Italy.ORCID 0000-0002-4025-7930
Francesco RaveraDepartment of Internal Medicine, University of Genoa, Genoa, Italy.
Anna GarutiDepartment of Internal Medicine, University of Genoa, Genoa, Italy.
Martina DameriDepartment of Internal Medicine, University of Genoa, Genoa, Italy.
Maurizio GalloDepartment of Internal Medicine, University of Genoa, Genoa, Italy.
Valentina BarberoIRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Fabio FerrandoIRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Lucia Del MastroDepartment of Internal Medicine, University of Genoa, Genoa, Italy.ORCID 0000-0002-9546-5841
Alessandro GarlaschiIRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Daniele FriedmanIRCCS Ospedale Policlinico San Martino, Genoa, Italy.ORCID 0000-0001-5240-8153
Piero FregattiIRCCS Ospedale Policlinico San Martino, Genoa, Italy.ORCID 0000-0002-1279-5299
Alberto BallestreroDepartment of Internal Medicine, University of Genoa, Genoa, Italy.
Gabriele ZoppoliDepartment of Internal Medicine, University of Genoa, Genoa, Italy.ORCID 0000-0002-1619-1708

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe study of plasma cell-free DNA integrity (cfDI) has shown potential for providing useful information in neoplastic patients. The aim of this study is to estimate the accuracy of an electrophoresis-based method for cfDI evaluation in the assessment of pathologic complete response (pCR) in patients with breast cancer (BC) undergoing neoadjuvant chemotherapy (NACT). PATIENTS AND

methodsFifty-one patients with BC undergoing anthracycline-/taxane-based NACT were recruited. Plasma samples were collected from each patient at diagnosis (t0), after anthracycline administration (t1), and after NACT completion (t2). The concentration of differently sized cell-free DNA fragments was assessed by automated electrophoresis. cfDI, expressed as cfDI index, was calculated as the ratio of 321-1,000 bp sized fragment concentration to 150-220 bp sized fragment concentration assessed at t2. cfDI index was then used to build an exploratory classifier for BC response to NACT, directly comparing its sensitivity and specificity with magnetic resonance imaging (MRI), through bootstrapped logistic regression.

resultscfDI index was assessed on 38 plasma samples collected from as many patients at t2, maintaining a 30/70 ratio between pCR and non-pCR patients. cfDI index showed an area under the receiver operating characteristic curve in predicting the achievement of pCR of 81.6, with a cutoff above 2.71 showing sensitivity = 81.8 and specificity = 81.5. The combination of cfDI index and MRI showed, in case of concordance, an area under the receiver operating characteristic curve of 92.6 with a predictive value of complete response of 87.5 and a predictive value of absence of complete response of 94.7.

conclusioncfDI index measured after NACT completion shows great potential in the assessment of pCR in patients with BC. The evaluation of its use in combination with MRI is strongly warranted in prospective studies.

Indexed as

Breast NeoplasmsCell-Free Nucleic AcidsElectrophoresisFemaleHumansNeoadjuvant TherapyProspective StudiesCell-Free Nucleic Acids

Identifiers

PMID35201850
PMCPMC8974578

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.